Breast Cancer Update: A CME Audio Series and Activity

STATMENT OF NEED / TARGET AUDIENCE
Breast cancer is one of the most rapidly evolving fields in medical oncology. Published results from a plethora of ongoing clinical trials lead to the continuous emergence of new therapeutic agents and changes in the indications for existing treatments. In order to offer optimal patient care — including the option of clinical trial participation — the practicing medical oncologist must be well-informed of these advances. To bridge the gap between research and patient care, Breast Cancer Update utilizes one-on-one discussions with leading oncology investigators. By providing access to the latest research developments and expert perspectives, this CME program assists medical oncologists in the formulation of up-to-date clinical management strategies.

Issue 5, 2002 of Breast Cancer Update consists of discussions with four oncology research leaders on a variety of important issues, including trastuzumab-related cardiac effects, the use of trastuzumab for metastatic disease, the use of adjuvant ovarian ablation with tamoxifen, clinical use of the estrogen downregulator, fulvestrant, the implications of the ATAC trial results on clinical practice, the effect of chemotherapy in older women and the current clinical trials being conducted by the NSABP.

EDUCATIONAL OBJECTIVES
Upon completion of this activity, participants should be able to:

• Review the role of trastuzumab in the treatment of metastatic disease
• Discuss the potential cardiac effects of trastuzumab
• Explain the rationale for adjuvant ovarian ablation
• Compare the mechanism of action for fulvestrant to that of tamoxifen and anastrozole
• Describe how ER status is currently measured and defined
• Explain the clinical implications of the ATAC trial results
• Review the effect of adjuvant chemotherapy in older women
• Discuss postmenopausal ovarian function
• Discuss the current clinical trials being conducted by the NSABP

ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Postgraduate Institute for Medicine and NL Communications, Inc. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

DESIGNATION STATEMENT
The Postgraduate Institute for Medicine designates this educational activity for a maximum of 3 hours in category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the activity.

FACULTY DISCLOSURE STATEMENTS
The Postgraduate Institute for Medicine has a conflict of interest policy that requires course faculty to disclose any real or apparent commercial financial affiliations related to the content of their presentations/materials. It is not assumed that these financial interests or affiliations will have an adverse impact on faculty presentations; they are simply noted in this supplement to fully inform participants.

Home · Search

Editor's Note    - Select Publications

George W Sledge, Jr, MD    - Select Publications

Anthony Howell, BSc, MBBS, MSc, FRCP    - Select Publications

I Craig Henderson, MD    - Select Publications

Eleftherios P Mamounas, MD    - Select Publications

INTERVIEWS: Full interview transcripts from audio program with relevant links

Editor's office

Faculty Financial Interest or Affiliations